The FDA moved to speed its review of psychedelic-derived medicines by issuing priority vouchers tied to three mental health programs. The agency’s move includes a voucher for Compass Pathways’ psilocybin candidate for treatment-resistant depression, a voucher for Usona Institute’s psilocybin-like medicine in major depressive disorder, and a voucher for Transcend Therapeutics’ MDMA-like program for PTSD. Separately, the FDA’s commissioner vouchers were described as surprising in market commentary, reflecting investor focus on which programs receive expedited pathways. The voucher framework is designed to add review acceleration rather than guarantee approval, but it can meaningfully alter timelines. For biotech developers in mental health, the decision tightens the link between policy-level incentives and near-term regulatory milestones.